Our study identifies PGRMC1 as a tumour-promoting factor and modulator of the tumour microenvironment that may serve as an independent prognostic marker for the overall survival of GBM patients and, most importantly, as a target for novel therapeutic strategies in GBM. This evidence concerns the gene PGRMC1 and neoplasm.